IntelligentMDx (IMDx) has received CE mark approval for its IMDx VanR test for the Abbott FDA cleared m2000 instrument.
The IMDx VanR for Abbott m2000 test distinguishes and detects the vanA and vanB genes found in vancomycin-resistant enterococci (VRE) and provides solution for early detection of pathogens associated with common healthcare-associated infections.
The automated nature of the VanR test aids clinicians to obtain results in less than 3 hours for up to 48 patient samples, and up to 94 patient samples in less than 4 hours.
IMDx chairman and CEO Alice Jacobs said at IMDx, they have developed proprietary software analytic tools, enabling them to produce tests that are sensitive, cost-effective, and rapid alternatives to existing culture-based screening methods for vancomycin-resistant infections.
"We are proud to offer physicians the ability to make timely, informed decisions about patient care in order to aid in preventing the spread of healthcare-associated infections," Jacobs said.